Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
03/2003
03/13/2003US20030050238 Stable composition comprising epidermal growth factor as an active ingredient
03/13/2003US20030050234 Conotoxin peptide extracted from the venom of a marine snail, Conus magnus (cono=cone); disorders associated with voltage gated sodium ion channel; neuromuscular blocking agents; local anesthetics; neuroprotective agents; analgesics
03/13/2003US20030049706 Nucleotide sequences coding polypeptide for use in the diagnosis, treatment and prevention of bacterial infections
03/13/2003US20030049697 Detection of potassium channel modulators for treatment of heart, vascular and endrocrine pathologies; obtain sample, incubate with modulator, monitor effect of modulator on transport protein activity
03/13/2003US20030049643 G protein-coupled receptors for use in the treatment of cardiovascular, nervous system, angina pectoris, inflamatory bowel, allergies and gastrointestinal disorders
03/13/2003US20030049331 Mixture of loop diuretics and lithium; contact lenses
03/13/2003US20030049245 Methods for sterilizing preparations of digestive enzymes
03/13/2003CA2459136A1 A caspase-8 binding protein, its preparation and use
03/13/2003CA2459045A1 Antidiabetic extracts of artemisia dracunculus
03/13/2003CA2457534A1 Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof
03/13/2003CA2456904A1 Aerosolized decongestants for the treatment of sinusitis
03/13/2003CA2455896A1 Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma
03/12/2003EP1291360A1 Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
03/12/2003EP1290193A2 Protein phosphatases
03/12/2003EP1290187A2 Humain kinases
03/12/2003EP1290180A2 Drug metabolizing enzymes
03/12/2003EP1289997A1 Macrolides
03/12/2003EP1289993A1 Caspase inhibitors and uses thereof
03/12/2003EP1289990A1 Tetracyclic diketopierazine compounds as pdev inhibitors
03/12/2003EP1289989A2 Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
03/12/2003EP1289983A2 Heteroarylalkanoic acids as integrin receptor antagonists
03/12/2003EP1289980A1 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides
03/12/2003EP1289961A1 Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
03/12/2003EP1289960A2 Cycloalkyl alkanoic acids as integrin receptor antagonists
03/12/2003EP1289959A1 Dihydrostilbene alkanoic acid derivatives useful as vitronectin antagonists
03/12/2003EP1289958A2 BENZOPHENONES AS INHIBITORS OF IL-1$g(b) AND TNF-$g(a)
03/12/2003EP1289956A1 Chemical compounds
03/12/2003EP1289945A1 Aniline disulfide derivatives for treating allergic diseases
03/12/2003EP1289944A2 Thioketals and thioethers for inhibiting the expression of vcam-1
03/12/2003EP1289916A2 Purification of xanthophylls from marigold extracts that contain high levels of chlorophylls
03/12/2003EP1289740A1 Crystalline polymeric compositions for ophthalmic devices
03/12/2003EP1289525A2 Tricyclic pyrazole derivatives as protein kinase inhibitors
03/12/2003EP1289507A1 Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
03/12/2003EP1289506A1 Novel composition
03/12/2003EP1289497A1 Novel aqueous anti-inflammatory pharmaceutical formulation
03/12/2003EP1289495A1 Process for the preparation of a sterile ointment containing acyclovir
03/12/2003EP1075285B1 The use of a vital dye for facilitating surgical procedures for cataract extraction
03/12/2003EP0787016B1 Secretory leukocyte protease inhibitor (slpi) as an inhibitor of tryptase
03/12/2003EP0652754B1 Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
03/12/2003CN1402721A Benzoimidazole derivs. useful as antiproliferative agents
03/12/2003CN1402634A Use of beta-adrenoceptor antagonists for manufacture of medicament for treatment of disorders of outer retina
03/12/2003CN1401352A Chinese medicinal pill and eye drops for treating myopia, and preparing process thereof
03/12/2003CN1401317A Use of bismuth subgallate in suppressing formation of nitrogen oxide synthetase
03/11/2003US6531612 Nitrile derivatives that inhibit cathepsin K
03/11/2003US6531580 Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
03/11/2003US6531511 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
03/11/2003US6531504 Prostanoic acid derivatives as agents for lowering intraocular pressure
03/11/2003US6531492 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
03/11/2003US6531471 Morpholinone and morpholine derivatives and uses thereof
03/11/2003US6531468 Inhibiting serotonin reuptake in the central nervous system of a mammal
03/11/2003US6531450 Use treating neuropathological situations caused by the aging of the nervous system; MP52, MP121 are growth or/and differentiation factors of the TGF-beta (transforming growth factor) superfamily
03/11/2003US6531120 Comprising histamine, its receptor analog, serotonin and its receptor analog in an opthalmic solution or gel for reducing irritation due to infection, allergies, pollutants and other irritants in a pharmaceutically acceptable carrier
03/11/2003CA2264254C Phosphinic acid amides as matrix metalloprotease inhibitors
03/07/2003WO2002020481A2 Substituted 4-phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridine
03/07/2003WO2002020472A1 Substituted phenylcyclohexane carboxylic acid amides and the use thereof
03/07/2003CA2421835A1 Substituted 4-phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridines
03/07/2003CA2421781A1 Substituted phenylcyclohexane carboxylic acid amides and the use thereof
03/06/2003WO2003018756A2 Methods for preparing purified prostaglandin e synthase
03/06/2003WO2003018619A2 Antimicrobial and anti-inflammatory peptides
03/06/2003WO2003018586A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease
03/06/2003WO2003018585A1 Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
03/06/2003WO2003018579A1 Alkyne-aryl phosphodiesterase-4 inhibitors
03/06/2003WO2003018576A1 New piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity
03/06/2003WO2003018556A1 Piperidine derivatives useful as modulators of chemokine receptor activity
03/06/2003WO2003018069A1 Preparation and diabetic use of gibberellins
03/06/2003WO2003018057A1 Remedy for glaucoma comprising as the active ingredient compound having pi3 kinase inhibitory effect
03/06/2003WO2003018052A1 Moraxella (branhamella) catarrhalis polypeptides and corresponding dna fragments
03/06/2003WO2003018049A2 Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection
03/06/2003WO2003018044A1 New drug
03/06/2003WO2003018031A2 Single dose azithromycin for treating respiratory infections
03/06/2003WO2003018028A1 Compositions comprising negatively charched phospholipids for treatment and/or prevention of macular degeneration and method for its manufacture
03/06/2003WO2003018025A1 Method and composition for treatment of ocular hypertension and glaucoma
03/06/2003WO2003018020A1 Jnk inhibitors
03/06/2003WO2003017990A2 Ophthalmic composition comprising an ascomycin
03/06/2003WO2003017946A2 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/06/2003WO2002096367A3 Targeted multivalent macromolecules
03/06/2003WO2002094830A3 DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
03/06/2003WO2002086069A3 Secreted proteins
03/06/2003WO2002083066A3 Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
03/06/2003WO2002041837A3 Treatment of mucositis
03/06/2003WO2002034726A9 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
03/06/2003WO2002030982A3 Endostatin and pitslre protein kinases as angiogenesis-inhibiting peptides and method of use
03/06/2003WO2002024672A3 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
03/06/2003WO2002020516A1 Novel crystals of 1,3,4-oxadiazole derivative, process for producing the crystals and medicines containing the same as the active ingredient
03/06/2003WO2001092304A3 Transporters and ion channels
03/06/2003WO2001077146A3 Compounds and methods for modulating endothelial cell adhesion
03/06/2003US20030045830 Inhibiting the expression of a specific gene involved in eye function by inducing or reverting a mutation in that gene by topically applying or injecting the chimeric oligonucleotide
03/06/2003US20030045728 Indol-3-yl derivatives
03/06/2003US20030045571 Process and intermediates to prepare latanoprost
03/06/2003US20030045556 Aryl-N-cyanoguanidines and methods related thereto
03/06/2003US20030045554 Such as 1-(2-thien-2'-yl- 2-oxoethyl)-3-((3-phenylmethyl) pyrazol-5-yl)pyridinium bromide for treating diseases caused by the accumulation of AGE (Advanced Glycation Endproducts); antidiabetic/ antiaging agents
03/06/2003US20030045540 Nicotinic acetylcholine receptors antagonists; central nervous system disorder treatments
03/06/2003US20030045524 Particularly quinoxaline, (2-imidozolin-2-ylamino) quinoxaline, or 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline and linolenic acid, which may be complexed with the quinoxaline agonist
03/06/2003US20030045517 Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
03/06/2003US20030045505 Oligosaccharide having at least a D-galactose unit bound by an alpha (1-6) bond with a sucrose unit; second component is a molecule positively charged at physiological pH and that promotes pinocytosis or membrane penetration
03/06/2003US20030045498 Contacting the ocular cell with an expression vector comprising the nucleic acid sequence encoding the inhibitor of angiogenesis and the nucleic acid sequence encoding the neurotrophic agent.
03/06/2003US20030045490 Therapeutic antisense phosphodiesterase inhibitors
03/06/2003US20030044893 Nectin polypeptides, polynucleotides, methods of making and use thereof
03/06/2003US20030044452 Composition for topical administration
03/06/2003CA2458565A1 New angiogenesis inhibitors based on soluble cd44 receptor hyaluronic acid binding domain
1 ... 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 ... 531